Study finds no link between PDE-5 inhibitors and central serous chorioretinopathy

This case-control study using records (2004 to 2005) from the National Veterans Health Administration showed no statistically significant association between central serous chorioretinopathy (CSC) and phosphodiesterase-5 (PDE-5) inhibitors. Of 577 men newly diagnosed with CSC and aged 59 years or younger, 111 (19.2 percent) bad been prescribed a PDE-5 inhibitor, compared to 18.5 percent and 21.5 percent of two age-matched control groups (acute conjunctivitis and macular pucker, respectively), each with 1,154 men.